Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Drops By 15.7%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 4,250,000 shares, a decrease of 15.7% from the January 31st total of 5,040,000 shares. Based on an average trading volume of 2,870,000 shares, the days-to-cover ratio is presently 1.5 days.

Institutional Trading of Reviva Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Tang Capital Management LLC purchased a new position in shares of Reviva Pharmaceuticals during the 4th quarter valued at approximately $308,000. Cornerstone Select Advisors LLC purchased a new position in Reviva Pharmaceuticals during the fourth quarter valued at $32,000. Ameriprise Financial Inc. acquired a new stake in shares of Reviva Pharmaceuticals in the fourth quarter valued at about $84,000. Tower Research Capital LLC TRC increased its stake in shares of Reviva Pharmaceuticals by 848.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after purchasing an additional 23,953 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter worth about $45,000. 63.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. HC Wainwright reduced their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. Finally, Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $11.40.

Reviva Pharmaceuticals Trading Up 0.4 %

RVPH traded up $0.01 on Wednesday, reaching $1.26. The stock had a trading volume of 351,072 shares, compared to its average volume of 1,836,978. The business’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $1.47. The company has a market cap of $41.97 million, a P/E ratio of -1.13 and a beta of -0.12. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.28.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.